The Effect of the Early Application of Tirofiban on Acute Ischemic Stroke (AIS) after Intravenous Thrombolysis with Urokinase

Objective:Discussion and analysis of the effect of the early application of Tirofiban on acute ischemic stroke(AIS)after intravenous thrombolysis with urokinase.Method:The subjects of this study are 40 patients with AIS admitted at the Yibin Fourth People’s Hospital,of which were computer-randomized into a control group(20 cases,with regular urokinase intravenous thrombolysis therapy)and a research group(20 cases,combined with early Tirofiban treatment)from January 2018 to December 2022.The intervention outcomes between these two groups were compared and analyzed.Result:The blood platelet-related parameters before treatment had no statistical difference between the two groups(P>0.05),but the research group was higher than that of the control group after treatment(P<0.05).The Barthel index before treatment in both groups had no statistical difference(P>0.05),but the research group was higher than that of the control group after treatment(P<0.05).Conclusion:Early Tirofiban treatment for patients with AIS after intravenous thrombolysis with urokinase could effectively regulate the blood platelet-related parameters,hence improving treatment benefits and living capacity for patients,with definite clinical benefits.

Effects of butyphthalide + rt-PA intravenous thrombolysis on the DWI characteristics, coagulation function and neurological function in patients with acute cerebral infarction

Objective: To investigate the effects of butyphthalide + alteplase (rt-PA) intravenous thrombolysis on the diffusion-weighted imaging (DWI) characteristics, coagulation function and neurological function in patients with acute cerebral infarction. Methods: The patients with acute cerebral infarction who were admitted to our hospital between April 2015 and October 2018 and with the onset time 4.5 hours were selected and divided into the observation group receiving butyphthalide + rt-PA intravenous thrombolysis and the control group receiving rt-PA intravenous thrombolysis by random number table. The differences in DWI parameter apparent diffusion coefficient (ADC), coagulation function indexes and neurological function indexes were compared between the two groups. Results: At 7 and 14 days after treatment, the ADC values of both groups were significantly increased, and the ADC values of the observation group were significantly higher than those of the control group;at 7 days after treatment, the prothrombin time (PT) and activated partial thromboplastin time (APTT) levels in both groups were significantly prolonged whereas fibrinogen (FIB), D-dimer (D-D), platelet activating factor (PAF), P-selectin, von Willebrand factor (vWF), neuron-specific enolase (NSE), S100B protein (S100B), malondialdehyde (MDA) and endothelin-1 (ET-1) contents were significantly decreased, and the APTT and PT levels in the observation group were significantly shorter than those in the control group whereas FIB, D-D, PAF, P-selectin, vWF, NSE, S100B, MDA and ET-1 contents were significantly lower than those in the control group. Conclusion: Butyphthalide + rt-PA intravenous thrombolysis can improve the DWI characteristics, coagulation function and neurological function of patients with acute cerebral infarction.

Anticoagulation effect of low-dose and low-intensity heparin applied within 24 hours after intravenous thrombolysis for acute cerebral infarction

BACKGROUND： Studies have demonstrated that immediate anticoagulation after thrombolysis can improve the prognosis of patients with acute cerebral infarction. However, the optimal timing and means of anticoagulation therapy remain unclear. OBJECTIVE： To observe the effects and safety of heparin treatment within 24 hours after intravenous thrombolysis for acute cerebral infarction. DESIGN： Observation experiment. SETTING： Department of Neurology, the 306 Hospital of Chinese PLA. PARTICIPANTS： Fifteen acute cerebral infarction patients complicated by moderate and severe neurologic function deficits within 6 hours after attack admitted to Department of Neurology, the 306 Hospital of Chinese PLA between January 2005 and December 2006 were recruited in this study. The involved patients, 11 male and 4 female, were aged 46- 79 years. They all met the diagnosis criteria for various cerebrovascular diseases formulated by the 4th National Conference for Cerebrovascular Disease （1995） and confirmed as cerebral infarction by skull CT or MRI imageology. Informed consents were obtained from the patients or their relatives. METHODS： On admission, patients received thrombolysis with urokinase. Immediately after thrombolysis, skull CT was rechecked. Intracranial hemorrhage signs were not found by skull CT. Hemorrhage was also not found in skin, mucous membrane and internal organs. Six hours later, low-dose low-intensity heparin 4 - 8 IU/kg per hour was intravenously administrated for anticoagulation for 7 - 10 days successively. MAIN OUTCOME MEASURES： Neurologic function was evaluated before, immediately 6 hours and 14 days after thrombolysis by scoring standard of clinical neurologic function deficit degree for stroke patients （1995）. Activities of daily living of patients with stroke were evaluated 90 days after thrombolysis by modified Rankin Scale. RESULTS： Fifteen involved patients participated in the final analysis. ① Comparison of clinical neurologic function deficit degree of patients at different time： Neurologic function deficit score at the end of thrombolysis was significantly lower than that before thrombolysis （t =3.45, P 〈 0.01）. Neurologic function deficit score 6 hours after thrombolysis was higher than that at the end of thrombolysis, and neurologic deficits were increased, but no significant difference was found （P 〉 0.05）. Neurologic function deficit score 14 days after thrombolysis was significantly lower than that before thrombolysis （t =4.769, P 〈 0.01）. ②Therapeutic effect and modified Rankin scale results： 14 days after thrombolysis, 4 patients were basically cured, 7 significantly improved, 2 improved and 2 worsened. The total improvement rate of neurologic function deficit was 86.7%. Ninety days after thrombolysis, according to modified Rankin Scale, score was 0 to 2 in 12 patients （80%）, 3 to 4 in 2 patients （13.3%） and 6 in 1 patient （6.7%）. Complications of intracranial hemorrhage were not found in patients within 14 days after thrombolysis. CONCLUSION： Low-dose and low-intensity heparin applied within 24 hours after intravenous thrombolysis has good safety and efficacy in the treatment of acute cerebral infarction.

Clinical study about mild hypothermia + intravenous thrombolysis in promoting the neural functional recovery in patients with acute cerebral infarction

Objective: To explore the efficacy of mild hypothermia + intravenous thrombolysis in promoting the neural functional recovery in patients with acute cerebral infarction. Methods: A total of 176 patients with acute cerebral infarction who were treated in our hospital between September 2015 and February 2017 were reviewed and divided into the routine group (n=100 cases, receiving routine intravenous thrombolysis therapy) and the mild hypothermia group (n=76, receiving mild hypothermia + intravenous thrombolysis therapy), and the treatment lasted for 1 week. The differences in serum levels of nerve injury indexes, inflammatory mediators and neurotransmitters were compared between the two groups before treatment and after 1 week of treatment. Results: Before treatment, there was no statistically significant difference in serum levels of nerve injury indexes, inflammatory mediators and neurotransmitters between the two groups. After 1 week of treatment, serum nerve injury indexes H-FABP, NT-proBNP, NSE and S100B levels of mild hypothermia group were lower than those of routine group;inflammatory mediators sICAM-1, IL-8, IL-13 and IL-18 levels were lower than those of routine group;neurotransmitter Glu level was lower than that of routine group whereas GABA level was higher than that of routine group. Conclusion: mild hypothermia + intravenous thrombolysis therapy can effectively reduce the nerve injury and systemic inflammatory response, and optimize the neurotransmitter distribution in patients with acute cerebral infarction.

Evaluation of serological indicators of intravenous thrombolysis bridge stent combined with aspiration embolectomy for intracranial macrovascular infarction

Objective: To explore the effect of intravenous thrombolysis bridge stent combined with aspiration embolectomy on serological indicators in patients with intracranial macrovascular infarction. Methods: 92 patients with intracranial macrovascular infarction who received treatment in our hospital between February 2016 and January 2018 were selected as the research subjects and divided into the control group (n=46) and the study group (n=46) by random number table method. Control group received stent embolectomy alone, and study group received intravenous thrombolysis bridge stent combined with aspiration embolectomy. The differences in serum levels of inflammatory mediators, chemokines and nerve function-related indexes were compared between the two groups before treatment and 24h after embolectomy. Results: Before treatment, the differences in serum levels of inflammatory mediators, chemokines and nerve function-related indexes were not significant between the two groups. 24h after embolectomy, serum inflammatory mediators sICAM-1, hs-CRP and TNF-α levels of study group were lower than those of control group;serum chemokines CXCL16, Fractalkine and MCP-1 contents were lower than those of control group;serum nerve function-related indexes IGF-1, BDNF and CNTF levels were higher than those of control group whereas NSE level was lower than that of control group. Conclusion:Intravenous thrombolysis bridge stent combined with aspiration embolectomy can effectively reduce the systemic inflammatory response and optimize the nerve function in patients with intracranial macrovascular infarction.

Intravenous thrombolysis for acute ischemic stroke with extended time window

Background:Intravenous thrombolysis(IVT)is an effective way for treating acute ischemic stroke(AIS).However,its effects have not been established among AIS patients with unclear stroke symptoms or with stroke onset for>4.5 h.Methods:We searched PubMed,Embase,Web of Science,Cochrane Central Register of Controlled Trials and Google Scholar databases for randomized controlled trials that compared IVT(IVT group)and placebo or usual care(control group[CG])in AIS patients with disease onset for>4.5 h.The outcomes of interest included the favorable functional outcome(defined as modified Rankin Scale[mRS]scores 0–1)at 90 days,the functional independence(defined as mRS scores 0–2)at 90 days,proportion of patients with symptomatic intracerebral hemorrhage(sICH)and death at 90 days.We assessed the risk of bias using the Cochrane tool.Pre-specified subgroup analyses were performed by age(70 years or>70 years),National Institute of Health Stroke Scale(NIHSS,10 or>10)and time window(4.5–9.0 h or>9.0 h).Results:Four trials involving 848 patients were eligible.The risk of bias of included trials was low.Patients in the IVT group were more likely to achieve favorable functional outcomes(45.8%vs.36.7%;OR 1.48,95%CI 1.12–1.96)and functional independence(63.8%vs.55.7%;OR 1.43,95%CI 1.08–1.90)at 90 days,but had higher risk of sICH(3.0%vs.0.5%;OR 5.28,95%CI 1.35–20.68)at 90 days than those in the CG.No significant difference in death at 90 days was found between the two groups(7.0%vs.4.1%;OR 1.80;95%CI 0.97–3.34).Conclusions:Use of IVT in patients with extended time window may improve their functional outcomes at 90 days,although IVT may induce increased risk of sICH.Care of these patients should well balance the potential benefits and harms of IVT.

Factors associated with early neurological deterioration after intravenous thrombolysis with alteplase in patients with acute ischemic stroke

Objective To investigate the risk factors of early neurological deterioration(END)after intravenous thrombolysis(IVT)in patients with acute ischemic stroke(AIS).Methods We screened consecutive AIS patients from January 2006 to May 2015 in Tangshan Gongren Hospital.In this study,all patients were treated with in-

The Chinese Stroke Association scientific statement:intravenous thrombolysis in acute ischaemic stroke

The most effective medical treatment for acute ischaemic stroke(AIS)is to offer intravenous thrombolysis during the ultra-early period of time after the onset.Even based on the Consensus of Chinese Experts on Intravenous Thrombolysis for AIS in 2012 and 2014 Chinese Guidelines on the Diagnosis and Treatment of AIS,the rate of thrombolysis for AIS in China remained around 2.4%,and the rate of intravenous tissue plasminogen activator usage was only about 1.6%in real world.The indication of thrombolysis for AIS has been expanded,and contraindications have been reduced with recently published studies.In order to facilitate the standardisation of treating AIS,improve the rate of thrombolysis and benefit patients who had a stroke,Chinese Stroke Association has organised and developed this scientific statement.

Early intravenous administration of tirofiban is recommended in patients with acute ischemic stroke treated with alteplase:a meta-analysis

Background:The occurrence of early neurological deterioration following intravenous thrombolysis(IVT)is considered a particularly ominous clinical event and is strongly correlated with poor outcomes.Initiating tirofiban within 24 h after IVT has been suggested as a better treatment option to achieve long-term functional outcomes.However,the rationality of this remedy is a controversial.The purpose of the study was to evaluate the safety and efficacy of early intravenous tirofiban administration after IVT in patients with acute ischemic stroke(AIS).Methods:Databases including PubMed,EMBASE,Cochrane Library,and Web of Science were searched for clinical trials on early tirofiban implementation after IVT in patients with AIS from inception to September 2022.Odds ratios(ORs)were generated for dichotomous variants via meta-analysis using STATA 17.0 MP.Results:Five clinical trials with 725 patients were eligible.The study outcomes demonstrated that early tirofiban administration after IVT was not associated with symptomatic intracranial hemorrhage(OR,0.78;95%confidence interval(CI),0.22–2.74;P=0.70),asymptomatic intracranial hemorrhage(OR,1.11;95%CI,0.52–2.37;P=0.80),systemic bleeding(OR,0.97;95%CI,0.42–2.23;P=0.94),and death(OR,1.05;95%CI,0.47–2.31;P=0.91),but may reduce the incidence of early neurological deterioration(OR,0.09;95%CI,0.02–0.50;P=0.01),and was significantly associated with 90-day excellent(modified Rankin scale score 0–1)(OR,2.01;95%CI,1.35–3.02;P=0.00)and favorable(modified Rankin scale score 0–2)(OR,2.30;95%CI,1.63–3.23;P=0.00)functional outcomes.Conclusion:The early intravenous administration of tirofiban after IVT in patients with AIS may be a safe and effective treatment strategy that improves long-term neurological functional outcomes without increasing the risk of adverse events.

Outcome of multimodal MRI-guided intravenous thrombolysis in patients with stroke with unknown time of onset

Objective Intravenous tissue plasminogen activator(tPA)is the standard therapy for patients with acute ischaemic stroke(AIS)within 4.5 hours of onset.Recent trials have expanded the endovascular treatment window to 24 hours.We investigated the efficacy and safety of using multimodal MRI to guide intravenous tPA treatment for patients with AIS of unknown time of onset(UTO).Methods Data on patients with AIS with UTO and within 4.5 hours of onset were reviewed.Data elements collected and analysed included:demographics,National Institutes of Health Stroke Scale(NIHSS)score at baseline and 2 hours,24 hours,7 days after thrombolysis and before discharge,the modified Rankin Scale(mRS)score at 3 months after discharge,imaging findings and any adverse event.results Forty-two patients with UTO and 62 in control group treated within 4.5 hours of onset were treated with intravenous tPA.The NIHSS scores after thrombolysis and/or before discharge in UTO group were significantly improved compared with the baseline(p<0.05).Between the two groups,no significant differences in NIHSS score were observed(p>0.05).Utilising the non-inferiority test,to compare mRS scores(0-2)at 3 months between the two groups,the difference was 5.2%(92%CI,OR 0.196).Patients in the UTO group had mRS scores of 0-2,which were non-inferior to the control group.Their incidence of adverse events was similar.Conclusions Utilising multimodal MRI to guide intravenous only thrombolysis for patients with AIS with UTO was safe and effective.In those patients with AIS between 6 and 24 hours of time of onset but without large arterial occlusion,intravenous thrombolysis could be considered an option.

Association between fluid-attenuated inversion recovery vascular hyperintensity and outcome varies with different lesion patterns in patients with intravenous thrombolysis

Background and purpose To evaluate relationship between fluid-attenuated inversion recovery vascular hyperintensity(FVH)after intravenous thrombolysis and outcomes in different lesion patterns on diffusion-weighted imaging(DWI).Methods Patients with severe internal carotid or intracranial artery stenosis who received intravenous thrombolysis from March 2012 to April 2019 were analysed.They were divided into four groups by DWI lesion patterns:border-zone infarct(BZ group),multiple lesions infarct(ML group),large territory infarct(LT group),and single cortical or subcortical lesion infarct(SL group).Logistic regression was performed to identify risk factors for outcome(unfavourable outcome,modified Rankin Scale(mRS)≥2;poor outcome,mRS≥3).Results Finally,203 participants(63.3±10.2 years old;BZ group,n=72;ML group,n=64;LT group,n=37;SL group,n=30)from 1190 patient cohorts were analysed.After adjusting for confounding factors,FVH(+)was associated with unfavourable outcome in total group(OR 3.02;95%CI 1.49 to 6.13;p=0.002),BZ group(OR 4.22;95%CI 1.25 to 14.25;p=0.021)and ML group(OR 5.44;95%CI 1.41 to 20.92;p=0.014)patients.FVH(+)was associated with poor outcome in total group(OR 2.25;95%CI 1.01 to 4.97;p=0.046),BZ group(OR 5.52;95%CI 0.98 to 31.07;p=0.053)and ML group(OR 4.09;95%CI 1.04 to 16.16;p=0.045)patients,which was marginal significance.FVH(+)was not associated with unfavourable or poor outcome in LT and SL groups.Conclusion This study suggests that association between FVH and outcome varies with different lesion patterns on DWI.The presence of FVH after intravenous thrombolysis may help to identify patients who require close observations in the hospitalisation in patients with border-zone and multiple lesion infarcts.

The therapeutic effect and prognosis of acute cerebral infarction patients with atrial fibrillation treated by intravenous thrombolysis with recombinant tissue plasminogen activator

Objective To investigate the efficacy and safety of intravenous thrombolysis with recombinant tissue plasminogen activator (rt-PA) in acute cerebral infarct patients with atrial fibrillation (AF) and the predicting factors of poor prognosis.Methods Totally 162 patients with acute cerebral infarct were treated with rt-PA within 4.5hours from the onset.According to past history and the electrocardiogram,the patients was classified into

Dramatic recovery from stroke following intravenous thrombolysis in a patient on prasugrel for recent percutaneous coronary angioplasty

The authors report the first case of thrombolysis in a patient already receiving both aspirin and prasugrel following a recent ischemic coronary event. A 55-year-old gentleman was treated for inferior wall myocardial infarction with aspirin, prasugrel and percutaneous angioplasty of right coronary artery. Three days following the procedure he developed acute ischemic stroke due to a left middle cerebral artery infarction with a National Institute of Health Stroke Scale (NIHSS) of 24 and was treated with alteplase. Therapy was interrupted after completion of 29 mg (for a body weight of 65 kg) dose due to oral bleeding. Fifteen minutes post thrombolysis NIHSS was 5 and dropped to zero after 12 h. This report highlights the benefits of alteplase in the context of several relative contraindications like the setting of acute myocardial infarction treated with percutaneous intervention and high NIHSS.

Relationship between total cerebral small vessel disease burden and hemorrhagic transformation of acute ischemic stroke patients after intravenous thrombolysis

Objective To investigate the relationship betweentotal cerebral small vessel disease (CSVD) burden andintracranial hemorrhage transformation (HT) after intravenousthrombolysis in patients with acute ischemicstroke (AIS). Methods One hundred and fifty-four patientswho suffered from ischemic stroke within 4. 5 hoursof onset and received recombinant tissue plasminogen activatorthrombolytic therapy in the emergency green channelof the First Affiliated Hospital of Soochow Universityfrom August 2016 to January 2018 were enrolled. HT examinedby computed tomography scan within 24 hours afterthrombolysis was included. The magnetic resonanceimaging examination was performed within 48 hours. Thepatients were divided into two groups: HT group andcontrol group according to the presence or absence ofHT.

Clinical effect and possible mechanism of intravenous thrombolysis combined with mild hypothermia on acute cerebral infarction

Objective To examine the effects of intravenous thrombolysis with tissue-type plasminogen activator(rtPA)combined with mild hypothermia therapy on patients with acute cerebral infarction and further investigate under-lying mechanism for the treatment of cerebral infarction.Methods Sixty cases of cerebral infarction patiens were randomly divided into three groups with 20

The relationship between T_2 white-matter hyperintensities and hemorrhagic transformation and neurological outcome after intravenous thrombolysis with recombinant tissue plasminogen activator in acute ischemic stroke

Objective To investigate the relationship between white-matter hyperintensities (WMHs) and hemorrhagictransformation (HT) and neurological outcome at 3months after recombinant tissue plasminogen activator (rtPA) treatment in patients with acute ischemic stroke.

Efficacy analysis of intravenous thrombolysis after cardiopulmonary resuscitation for patients with acute myocardial infarction and cardiac arrest

Objective To explore the clinical value of intravenous thrombolysis in the treatment of patients with acute myocardial infarction(AMI)and cardiac arrest after cardiopulmonary resuscitation.Methods 120 patients with AMI and cardiac arrest admitted in our hospital from Mar2009 to Mar 2013 were divided into thrombolytic group(n=50)and control group(n=70)according to

Correlation between blood pressure variability and symptomatic intracerebral hemorrhage of ischemic stroke after intravenous thrombolysis

Objective To explore the value of early blood pressure variability(BPV)in predicting the risk of symptomatic intracerebral hemorrhage(sICH)after intravenous thrombolysis(IVT)in acute ischemic stroke(AIS).Methods AIS patients were collected who received recombinant tissue plasminogen activator IVT within 4.5 hours of onset from 2012 to 2016 with complete clinical data.According to skull CT or MRI findings and NIHSS scores within 48 hours after IVT therapy,the patients were divided into sICH group(22 cases)and non-sICH group(157 cases).The differences of sICH risk factors between the two groups were analyzed by single factor t test,χ^2 test and multivariate Logistic regression analysis.The 24-hour systolic blood pressure standard deviation(24hSBPsd)and 24-hour diastolic blood pressure standard deviation(24hDBPsd)were further divided into four groups in quartiles,with the lowest quartile group as the reference group,and the rest groups were compared with the reference group,respectively.Results Univariate analysis showed that age,fibrinogen(FIB),smoking history,24hSBPsd and 24hDBPsd in sICH group were higher than those in non-sICH group(all P<0.05).Multivariate Logistic regression analysis showed that age(OR 3.117,95%CI 1.089-8.920),smoking history(OR 2.933,95%CI 1.042-8.257)and 24hSBPsd(OR 4.135,95%CI 1.397-12.237)in sICH group were still higher than those in non-sICH group(all P<0.05);There was no significant difference in FIB and 24hDBPsd between the two groups(P>0.05).After adjusting for risk factors of age and smoking history,the risks of sICH in 24hSBPsd and 24hDBPsd of the highest quartile group were 10.882 times(95%CI 2.088-56.717)and 6.025 times(95%CI 1.550-23.417)higher than those of the lowest quartile group,respectively,and the differences were statistically sigificant(P<0.05).Conclusion The higher the early BPV,the higher the risk of sICH after IVT,and the more obvious the influence of systolic blood pressure variability.

阿替普酶静脉溶栓治疗脑梗死患者的再闭塞影响因素及替罗非班治疗效果

目的探讨脑梗死患者阿替普酶静脉溶栓后再闭塞的影响因素及替罗非班的治疗效果。方法选取100例脑梗死患者作为研究对象,根据阿替普酶静脉溶栓后是否再闭塞分为闭塞组(n=42)和非闭塞组(n=58)。闭塞组给予替罗非班治疗。比较2组一般资料。采用Logistic回归模型分析脑梗死患者阿替普酶静脉溶栓后再闭塞的影响因素。观察闭塞组治疗总有效率、重组人组织型纤溶酶原激酶衍生物(rPA)、纤溶酶原激活物抑制剂1(PAI-1)水平以及美国国立卫生研究院卒中量表(NIHSS)、简易精神状态量表(MMSE)评分。结果2组在2型糖尿病、血糖、收缩压、NIHSS评分、起病-溶栓时间方面比较,差异有统计学意义(P<0.05)。Logistic回归分析显示,2型糖尿病、血糖、收缩压、NIHSS评分、起病-溶栓时间是脑梗死患者阿替普酶静脉溶栓后再闭塞的影响因素(P<0.05)。42例溶栓后再闭塞患者经替罗非班治疗后总有效率为88.10%(37/42)。治疗3、7 d,rPA高于治疗前,PAI-1低于治疗前,差异有统计学意义(P<0.05);治疗1、2、4周,MMSE评分高于治疗前,NIHSS评分低于治疗前,差异有统计学意义(P<0.05)。结论2型糖尿病、血糖、收缩压、NIHSS评分、起病-溶栓时间可对脑梗死患者阿替普酶静脉溶栓后再闭塞产生影响。再闭塞后予以替罗非班治疗的效果较为理想,有利于改善患者神经功能与rPA、PAI-1水平。

急性脑梗死介入治疗联合静脉溶栓治疗的效果观察

目的 探究介入治疗联合静脉溶栓对急性脑梗死患者的治疗效果。方法 80例急性脑梗死患者,合理且随机划分为对照组和观察组,每组40例。对照组采取静脉溶栓治疗,观察组在对照组基础上采用介入治疗。比较两组患者神经功能缺损评分、血清学相关指标(神经生长因子、神经元特异性烯醇化酶、脑钠肽)、活化部分凝血活酶时间、凝血酶原时间、凝血酶时间、纤维蛋白原、并发症发生情况。结果 观察组患者治疗后1 d、7 d、2周神经功能缺损评分均低于对照组(P<0.05)。治疗后,两组患者神经生长因子、神经元特异性烯醇化酶、脑钠肽水平均下降,且观察组患者神经生长因子(95.31±9.65)ng/ml、神经元特异性烯醇化酶(10.26±1.37)μg/L、脑钠肽(157.43±13.25)ng/L均低于对照组的(116.38±10.46)ng/ml、(15.86±1.86)μg/L、(189.46±17.78)ng/L(P<0.05)。治疗后,观察组患者活化部分凝血活酶时间(35.43±2.21)s、凝血酶原时间(13.26±1.53)s、凝血酶时间(17.46±2.24)s比对照组的(30.48±2.15)、(10.93±1.29)、(15.55±1.87)s更长,纤维蛋白原(2.44±0.43)g/L比对照组的(4.21±0.64)g/L更低(P<0.05)。观察组并发症发生率5.00%比对照组的25.00%更低(P<0.05)。结论 针对急性脑梗死患者,采取静脉溶栓联合介入治疗可有效改善患者神经功能及血清学状况,且可以有效改善活化部分凝血活酶时间等相关临床指标,减少相关并发症的发生,该治疗方案临床应用效果理想,预后效果良好,值得在临床广泛推广。